TMEM106B Polyclonal antibody

• Featured Product
• KD/KO Validated

TMEM106B Polyclonal Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

Human

Applications

WB, ELISA

Conjugate

Unconjugated

Cat no : 30301-1-AP

Synonyms

FLJ11273, TMEM106B, transmembrane protein 106B

---

Validation Data Gallery

• 

  WB analysis using 30301-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 30301-1-AP (TMEM106B antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HeLa using 30301-1-AP

  WB result of TMEM106B antibody (30301-1-AP; 1:600; room temperature for 1.5 hours) with negative control and TMEM106B knockout HeLa cells.

---

Tested Applications

• Positive WB detected in: A549 cells, HeLa cells

Recommended dilution

• Western Blot (WB): WB : 1:500-1:2000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

30301-1-AP targets TMEM106B in WB, ELISA applications and shows reactivity with Human samples.

• Tested Reactivity: Human
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: Peptide
• Full Name: transmembrane protein 106B
• Calculated Molecular Weight: 31 kDa
• Observed Molecular Weight: 45 kDa
• GenBank Accession Number: BC033901
• Gene Symbol: TMEM106B
• Gene ID (NCBI): 54664
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

TMEM106B is a genetic risk factor for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). Amyotrophic lateral sclerosis (ALS), like FTLD-TDP, is characterized by pathological TDP-43 inclusions. TMEM106B expression in the brain may be linked to mechanisms of disease in FTLD-TDP and risk alleles confer genetic susceptibility by increasing gene expression. TMEM106B can be showed as 31-55 kDa and 70-90 kDa (Glycosylated or Dimer) form in western blot test. (PMID: 27543298, 22895706, PMID: 23136129).